Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 GEN0101 + pembrolizumab in advanced melanoma
jRCT1091220410Phase 2Recruiting
- Sponsor
- Osaka University Hospital
- Start
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GEN0101 and pembrolizumab in melanoma, sponsored by Osaka University Hospital. Primary endpoints: Dose-limiting toxicity (DLT) incidence and Objective response rate (ORR). Started Feb 2019; status: recruiting.
02
Drugs
GEN0101pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT1091220410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220410.